Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

New SNRI approved for ADHD: Viloxazine

Posted by PeterMartin on April 6, 2021, at 10:16:29

A new SNRI, Viloxazine/Qelbree, was approved by the FDA (April 5, 2021):

Viloxazine, like imipramine, inhibited norepinephrine reuptake in the hearts of rats and mice; unlike imipramine, it did not block reuptake of norepinephrine in either the medullae or the hypothalami of rats. As for serotonin, while its reuptake inhibition was comparable to that of desipramine (i.e., very weak), viloxazine did potentiate serotonin-mediated brain functions in a manner similar to amitriptyline and imipramine, which are relatively potent inhibitors of serotonin reuptake.[11] Unlike any of the other drugs tested, it did not exhibit any anticholinergic effects.[11]

More recent research has found that the mechanism of action of viloxazine may be more complex than previously assumed.[12] It appears to act as a potent antagonist of 5-HT2B receptors and as a potent agonist of 5-HT2C receptors.[12] These actions may be involved in its effectiveness for ADHD.[12]

It has also been found to up-regulate GABAB receptors in the frontal cortex of rats.[13]
The Food and Drug Administration (FDA) has approved Qelbree (viloxazine extended-release capsules; Supernus Pharmaceuticals), a serotonin norepinephrine reuptake inhibitor, for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients 6 to 17 years of age.




Post a new follow-up

Your message only Include above post

Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.


Start a new thread

Google www
Search options and examples
[amazon] for

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:PeterMartin thread:1114436